These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
149 related articles for article (PubMed ID: 36985586)
21. Remdesivir and SARS-CoV-2: Structural requirements at both nsp12 RdRp and nsp14 Exonuclease active-sites. Shannon A; Le NT; Selisko B; Eydoux C; Alvarez K; Guillemot JC; Decroly E; Peersen O; Ferron F; Canard B Antiviral Res; 2020 Jun; 178():104793. PubMed ID: 32283108 [TBL] [Abstract][Full Text] [Related]
22. Remdesivir for the treatment of COVID-19. Ansems K; Grundeis F; Dahms K; Mikolajewska A; Thieme V; Piechotta V; Metzendorf MI; Stegemann M; Benstoem C; Fichtner F Cochrane Database Syst Rev; 2021 Aug; 8(8):CD014962. PubMed ID: 34350582 [TBL] [Abstract][Full Text] [Related]
23. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Wang Y; Zhang D; Du G; Du R; Zhao J; Jin Y; Fu S; Gao L; Cheng Z; Lu Q; Hu Y; Luo G; Wang K; Lu Y; Li H; Wang S; Ruan S; Yang C; Mei C; Wang Y; Ding D; Wu F; Tang X; Ye X; Ye Y; Liu B; Yang J; Yin W; Wang A; Fan G; Zhou F; Liu Z; Gu X; Xu J; Shang L; Zhang Y; Cao L; Guo T; Wan Y; Qin H; Jiang Y; Jaki T; Hayden FG; Horby PW; Cao B; Wang C Lancet; 2020 May; 395(10236):1569-1578. PubMed ID: 32423584 [TBL] [Abstract][Full Text] [Related]
24. Pyrimidine inhibitors synergize with nucleoside analogues to block SARS-CoV-2. Schultz DC; Johnson RM; Ayyanathan K; Miller J; Whig K; Kamalia B; Dittmar M; Weston S; Hammond HL; Dillen C; Ardanuy J; Taylor L; Lee JS; Li M; Lee E; Shoffler C; Petucci C; Constant S; Ferrer M; Thaiss CA; Frieman MB; Cherry S Nature; 2022 Apr; 604(7904):134-140. PubMed ID: 35130559 [TBL] [Abstract][Full Text] [Related]
25. Remdesivir, Renal Function and Short-Term Clinical Outcomes in Elderly COVID-19 Pneumonia Patients: A Single-Centre Study. Biancalana E; Chiriacò M; Sciarrone P; Mengozzi A; Mechelli S; Taddei S; Solini A Clin Interv Aging; 2021; 16():1037-1046. PubMed ID: 34113086 [TBL] [Abstract][Full Text] [Related]
26. Comparison of Binding Site of Remdesivir and Its Metabolites with NSP12-NSP7-NSP8, and NSP3 of SARS CoV-2 Virus and Alternative Potential Drugs for COVID-19 Treatment. Jung LS; Gund TM; Narayan M Protein J; 2020 Dec; 39(6):619-630. PubMed ID: 33185784 [TBL] [Abstract][Full Text] [Related]
27. A Review on Remdesivir: A Broad-spectrum Antiviral Molecule for Possible COVID-19 Treatment. Khazir J; Maqbool T; Mir BA Mini Rev Med Chem; 2021; 21(17):2530-2543. PubMed ID: 33596800 [TBL] [Abstract][Full Text] [Related]
28. Insights into antiviral mechanisms of remdesivir, lopinavir/ritonavir and chloroquine/hydroxychloroquine affecting the new SARS-CoV-2. Uzunova K; Filipova E; Pavlova V; Vekov T Biomed Pharmacother; 2020 Nov; 131():110668. PubMed ID: 32861965 [TBL] [Abstract][Full Text] [Related]
29. Antiviral Lipid Nanocarrier Loaded with Remdesivir Effective Against SARS-CoV-2 in vitro Model. Jeon WJ; Lee HK; Na YG; Jung M; Han SC; Hwang JH; Jung E; Hwang D; Shin JS; Cho CW Int J Nanomedicine; 2023; 18():1561-1575. PubMed ID: 37007987 [TBL] [Abstract][Full Text] [Related]
30. Cyanorona-20: The first potent anti-SARS-CoV-2 agent. Rabie AM Int Immunopharmacol; 2021 Sep; 98():107831. PubMed ID: 34247016 [TBL] [Abstract][Full Text] [Related]
31. The FDA-Approved Drug Cobicistat Synergizes with Remdesivir To Inhibit SARS-CoV-2 Replication Shytaj IL; Fares M; Gallucci L; Lucic B; Tolba MM; Zimmermann L; Adler JM; Xing N; Bushe J; Gruber AD; Ambiel I; Taha Ayoub A; Cortese M; Neufeldt CJ; Stolp B; Sobhy MH; Fathy M; Zhao M; Laketa V; Diaz RS; Sutton RE; Chlanda P; Boulant S; Bartenschlager R; Stanifer ML; Fackler OT; Trimpert J; Savarino A; Lusic M mBio; 2022 Apr; 13(2):e0370521. PubMed ID: 35229634 [TBL] [Abstract][Full Text] [Related]
33. Why Remdesivir Failed: Preclinical Assumptions Overestimate the Clinical Efficacy of Remdesivir for COVID-19 and Ebola. Yan VC; Muller FL Antimicrob Agents Chemother; 2021 Sep; 65(10):e0111721. PubMed ID: 34252308 [TBL] [Abstract][Full Text] [Related]
34. Impact of Remdesivir Incorporation along the Primer Strand on SARS-CoV-2 RNA-Dependent RNA Polymerase. Naseem-Khan S; Berger MB; Leddin EM; Maghsoud Y; Cisneros GA J Chem Inf Model; 2022 May; 62(10):2456-2465. PubMed ID: 35435671 [TBL] [Abstract][Full Text] [Related]
35. Sofosbuvir terminated RNA is more resistant to SARS-CoV-2 proofreader than RNA terminated by Remdesivir. Jockusch S; Tao C; Li X; Chien M; Kumar S; Morozova I; Kalachikov S; Russo JJ; Ju J Sci Rep; 2020 Oct; 10(1):16577. PubMed ID: 33024223 [TBL] [Abstract][Full Text] [Related]
36. Antiviral activity and safety of remdesivir against SARS-CoV-2 infection in human pluripotent stem cell-derived cardiomyocytes. Choi SW; Shin JS; Park SJ; Jung E; Park YG; Lee J; Kim SJ; Park HJ; Lee JH; Park SM; Moon SH; Ban K; Go YY Antiviral Res; 2020 Dec; 184():104955. PubMed ID: 33091434 [TBL] [Abstract][Full Text] [Related]
37. Remdesivir: Review of Pharmacology, Pre-clinical Data, and Emerging Clinical Experience for COVID-19. Jorgensen SCJ; Kebriaei R; Dresser LD Pharmacotherapy; 2020 Jul; 40(7):659-671. PubMed ID: 32446287 [TBL] [Abstract][Full Text] [Related]